Anticoagulant treatment in primary health care in Finland
- 1 January 1996
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 14 (3) , 165-170
- https://doi.org/10.3109/02813439609024172
Abstract
Objective - To establish the prevalence of anticoagulant (AC) treatment, the indica-tions, and the quality of care in primary health care. Design - A cross-sectional study, in which patients on AC treatment were identified from laboratory records. The main and second indications for AC treatment and the last value of the AC-test were taken from medical records. Setting - Eight Finnish health centres with a total population of 182 091 inhabitants. Results - A total of 1255 patients on AC treatment were identified, 48% of them men. The mean age was 68.9 years. The age-adjusted prevalence of AC treatment was 0.65%. The commonest main indication was atrial fibrillation (38%). It was the main or second indication in 591 patients (age-adjusted prevalence 0.30%). The next commonest main indication was deep vein thrombosis (15%), followed by pulmon-ary embolism (8%). A total of 274 (22%) patients were anticoagulated for cerebral circulatory disturbances. 86% of the latest prothrombin time values fell within recommended ranges. Conclusion - The prevalence of AC treatment in Finland seems to be high. The proportion of patients with atrial fibrillation is high, differing from the results in other countries. The monitoring of AC-treatment as the general practioner's re-sponsibility functions well. The quality of care is good, even in older age groups.Keywords
This publication has 5 references indexed in Scilit:
- How To Do It: Commentary: Caution needed in introducing warfarin treatmentBMJ, 1995
- How To Do It: Service provision and use of anticoagulants in atrial fibrillationBMJ, 1995
- Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Cardiogenic embolism to the brainThe Lancet, 1992
- PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATIONThe Lancet, 1989